speb/financial-data huggingface dataset:
Financial ratios for GRNQ — quarterly report dated 2025-06-30
Total revenue: 100967.37588652481
Gross profit: 81155.55555555555
Operating income: -142236.64302600472
Net income: -135727.65957446807
Capital expenditures: 0
Operating cash flow: -125704.96453900708
Depreciation & amortization: 14047.281323877067
Net tangible assets: 1128120.330969267
Owner earnings: -121680.378250591
Return on net tangible assets (%): -10.786116951375632
Buffett classification: The Gruesome
Stock price: 1.57
Shares outstanding: 18127663
Book value: 1138517.0212765955
P/B ratio: 24.99780888483152
Market cap (USD): 28460430.91
Debt to equity: 0.016652661055701217
Current ratio: 1.6744274065911586
Quick ratio: 1.6744274065911586
Interest coverage ratio: -2615.9173913043483
COGS to revenue (%): 19.622001816938738
SG&A to revenue (%): 221.2518614256413
Free cash flow (dilution-adjusted): -125704.96453900708
Buyback yield (%): 0
Retained earnings: -9095527.895981086
Receivables turnover: 0.3216952928867929
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -12.470469580818316
FCF margin (%): -124.50057598831165
Revenue growth (%): 26.79777045748604
Rule of 40 score: -97.70280553082561
Financial ratios for GRNQ — quarterly report dated 2025-09-30
Total revenue: 93403.32541567695
Gross profit: 62722.327790973875
Operating income: -123645.8432304038
Net income: -121906.4133016627
Capital expenditures: 308.55106888361047
Operating cash flow: -96888.36104513064
Depreciation & amortization: 14230.64133016627
Net tangible assets: 1018146.080760095
Owner earnings: -107984.32304038004
Return on net tangible assets (%): -10.605975417571175
Buffett classification: The Gruesome
Stock price: 1.37
Shares outstanding: 18127663
Book value: 1028577.1971496438
P/B ratio: 24.144904610778443
Market cap (USD): 24834898.310000002
Debt to equity: 0.01291223953943251
Current ratio: 1.4061385180756079
Quick ratio: 1.4061385180756079
Interest coverage ratio: -2432.4719626168226
COGS to revenue (%): 32.847864343332624
SG&A to revenue (%): 199.5305522495855
Free cash flow (dilution-adjusted): -97196.91211401425
Buyback yield (%): 0
Retained earnings: -9260643.46793349
Receivables turnover: 0.38834111540375904
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -11.999760257907164
FCF margin (%): -104.06151138779538
Revenue growth (%): -7.49157874455303
Rule of 40 score: -111.5530901323484
Financial ratios for GRNQ — annual report dated 2025-12-31
Total revenue: 511989.3827160494
Gross profit: 411398.51851851854
Operating income: -531460.7407407408
Net income: -736378.5185185185
Capital expenditures: 688.3950617283951
Operating cash flow: -442037.0370370371
Depreciation & amortization: 59295.555555555555
Net tangible assets: 877291.8518518519
Owner earnings: -677771.3580246915
Return on net tangible assets (%): -77.25722706691074
Buffett classification: The Gruesome
Stock price: 1.85
Shares outstanding: 18127663
Book value: 886628.1481481481
P/B ratio: 37.82439867270759
Market cap (USD): 33536176.55
Debt to equity: 0.008679018080429004
Current ratio: 1.628445529289133
Quick ratio: 1.628445529289133
Interest coverage ratio: -2437.617214043035
COGS to revenue (%): 19.64706058237126
SG&A to revenue (%): 184.15601789581865
Free cash flow (dilution-adjusted): -442725.43209876545
Buyback yield (%): 0
Retained earnings: -9937459.75308642
Receivables turnover: 2.0643808272229935
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -59.827938972842766
FCF margin (%): -86.47160410830278
Revenue growth (%): -34.69084253930593
Rule of 40 score: -121.16244664760872
Financial ratios for GRNQ — quarterly report dated 2025-12-31
Total revenue: 222341.23456790124
Gross profit: 197457.2839506173
Operating income: -84264.93827160494
Net income: -310963.7037037037
Capital expenditures: 367.65432098765433
Operating cash flow: -150537.2839506173
Depreciation & amortization: 15011.851851851852
Net tangible assets: 877291.8518518519
Owner earnings: -296319.5061728395
Return on net tangible assets (%): -33.77661670370545
Buffett classification: The Gruesome
Stock price: 1.85
Shares outstanding: 18127663
Book value: 886628.1481481481
P/B ratio: 37.82439867270759
Market cap (USD): 33536176.55
Debt to equity: 0.008679018080429004
Current ratio: 1.628445529289133
Quick ratio: 1.628445529289133
Interest coverage ratio: -1681.1477832512317
COGS to revenue (%): 11.191783955703723
SG&A to revenue (%): 126.70714128655543
Free cash flow (dilution-adjusted): -150904.93827160494
Buyback yield (%): 0
Retained earnings: -9937459.75308642
Receivables turnover: 0.8964970705215317
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -9.485926613200686
FCF margin (%): -67.87087359880597
Revenue growth (%): 138.0442383377746
Rule of 40 score: 70.17336473896863
Financial ratios for GSK — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 36.8
Shares outstanding: 2002797682
Market cap (USD): 73702954697.59999
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for GSK — annual report dated 2022-12-31
Total revenue: 35330120481.92771
Gross profit: 23819277108.433735
Operating income: 8107228915.662651
Net income: 18820481927.710846
Capital expenditures: 1201204819.2771084
Operating cash flow: 8919277108.433735
Depreciation & amortization: 2586746987.9518075
Net tangible assets: -12971084337.349398
Owner earnings: 20206024096.385548
Return on net tangible assets (%): -155.7774475199703
Capex to operating income (%): 14.816466042502599
Buffett classification: The Great
Stock price: 30.63
P/E ratio: 3.2595176486599957
Shares outstanding: 2002797682
Book value: 12163855421.686737
P/B ratio: 5.043277059203431
Market cap (USD): 61345692999.659996
Debt to equity: 2.0787440570522997
Current ratio: 0.9105217010083296
Quick ratio: 0.684918895221394
Effective tax rate (%): 12.56218905472637
Interest coverage ratio: 8.146489104116224
COGS to revenue (%): 32.580821170372396
R&D to revenue (%): 18.715045696357933
SG&A to revenue (%): 28.54999317964807
Free cash flow (dilution-adjusted): 5781927710.843373
Buyback yield (%): 0
Retained earnings: 5256626506.0240965
Inventory turnover: 1.8565876408861253
Receivables turnover: 5.378576669112252
Capitalized R&D asset: 6612048192.771085
ROCI (R&D-adjusted, %): 24.256647362849492
FCF margin (%): 16.36543445641795
Rule of 40 score: 16.36543445641795
Financial ratios for GSK — annual report dated 2023-12-31
Total revenue: 38389873417.72152
Gross profit: 27548101265.822784
Operating income: 9297468354.43038
Net income: 6718987341.772152
Capital expenditures: 1627848101.2658226
Operating cash flow: 8567088607.594936
Depreciation & amortization: 2903797468.35443
Net tangible assets: -10420253164.556961
Owner earnings: 7994936708.860761
Return on net tangible assets (%): -76.72497570456756
Capex to operating income (%): 17.508509189925118
Buffett classification: The Great
Stock price: 33.6
P/E ratio: 10.015497677281086
Shares outstanding: 2002797682
Book value: 16196202531.645569
P/B ratio: 4.154924710512544
Market cap (USD): 67294002115.200005
Debt to equity: 1.4082063305978898
Current ratio: 0.8849439908866528
Quick ratio: 0.6239794949686729
Effective tax rate (%): 12.467018469656992
Interest coverage ratio: 10.13103448275862
COGS to revenue (%): 28.241229227116854
R&D to revenue (%): 20.518992350303346
SG&A to revenue (%): 30.945001318913214
Free cash flow (dilution-adjusted): 5211392405.063292
Buyback yield (%): 0
Retained earnings: 9163291139.240505
Inventory turnover: 1.5578392142597306
Receivables turnover: 5.135986452159187
Capitalized R&D asset: 12307287479.030045
ROCI (R&D-adjusted, %): 20.46274376454563
Rosenberg metric: 0.5639438867771339
FCF margin (%): 13.574914270640992
Revenue growth (%): 8.660465614202908
Rule of 40 score: 22.2353798848439
Financial ratios for GSK — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 38.1
Shares outstanding: 2002797682
Market cap (USD): 76306591684.2
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for GSK — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 31.88
Shares outstanding: 2002797682
Market cap (USD): 63849190102.159996
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for GSK — annual report dated 2024-12-31
Total revenue: 39220000000
Gross profit: 27910000000
Operating income: 6927500000
Net income: 3688750000
Capital expenditures: 1667500000
Operating cash flow: 8192500000
Depreciation & amortization: 3188750000
Net tangible assets: -11032500000
Owner earnings: 5210000000
Return on net tangible assets (%): -47.22411058237027
Capex to operating income (%): 24.070732587513533
Buffett classification: The Great
Stock price: 31.88
P/E ratio: 17.309167089707895
Shares outstanding: 2002797682
Book value: 16357500000
P/B ratio: 3.9033587102038823
Market cap (USD): 63849190102.159996
Debt to equity: 1.2980284273269143
Current ratio: 0.7833801908097894
Quick ratio: 0.522099829469512
Effective tax rate (%): 15.127983894161634
Interest coverage ratio: 8.659375
COGS to revenue (%): 28.83732789393167
R&D to revenue (%): 20.400943396226413
SG&A to revenue (%): 35.10645079041305
Free cash flow (dilution-adjusted): 4035000000
Buyback yield (%): 0
Retained earnings: 9745000000
Inventory turnover: 1.5960486858352443
Receivables turnover: 5.640122236203488
Capitalized R&D asset: 15460960080.829649
ROCI (R&D-adjusted, %): 11.859094983664034
Rosenberg metric: 0.04594247147677974
FCF margin (%): 10.288118306986231
Revenue growth (%): 2.162358216829331
Rule of 40 score: 12.450476523815562
Financial ratios for GSK — quarterly report dated 2025-03-31
Total revenue: 9761038961.038961
Gross profit: 7245454545.454545
Operating income: 2877922077.9220777
Net income: 2301298701.2987013
Capital expenditures: 268831168.83116883
Operating cash flow: 1487012987.012987
Depreciation & amortization: 1068831168.8311688
Net tangible assets: -11723376623.376623
Owner earnings: 3101298701.2987013
Return on net tangible assets (%): -26.453971419076105
Capex to operating income (%): 9.341155234657041
Buffett classification: The Great
Stock price: 36.91
P/E ratio: 8.030602720205614
Shares outstanding: 2002797682
Book value: 17732467532.467537
P/B ratio: 4.168808560188763
Market cap (USD): 73923262442.62
Debt to equity: 1.3499340852497435
Current ratio: 0.8681772358504152
Quick ratio: 0.5801449762373385
Effective tax rate (%): 15.939278937381404
Interest coverage ratio: 13.679012345679011
COGS to revenue (%): 25.771687067589138
R&D to revenue (%): 19.451836083022883
SG&A to revenue (%): 27.541245343267697
Free cash flow (dilution-adjusted): 905194805.1948051
Buyback yield (%): 0.43393542192244683
Retained earnings: 10788311688.311687
Inventory turnover: 0.3228333333333333
Receivables turnover: 1.0647400481654627
Capitalized R&D asset: 1898701298.7012987
ROCI (R&D-adjusted, %): 7.718856847945293
FCF margin (%): 9.273549760510909
Rule of 40 score: 9.273549760510909
Financial ratios for GSK — quarterly report dated 2025-06-30
Total revenue: 10939726027.39726
Gross profit: 7973972602.739726
Operating income: 2771232876.712329
Net income: 2254794520.547945
Capital expenditures: 343835616.43835616
Operating cash flow: 2871232876.712329
Depreciation & amortization: 1587671232.8767123
Net tangible assets: -10026027397.260275
Owner earnings: 3498630136.9863014
Return on net tangible assets (%): -34.895477524251945
Capex to operating income (%): 12.40731586752348
Buffett classification: The Great
Stock price: 37.01
P/E ratio: 16.269101311490886
Shares outstanding: 2002797682
Book value: 19663013698.630142
P/B ratio: 3.769693870272996
Market cap (USD): 74123542210.81999
Debt to equity: 1.2090009753378845
Current ratio: 0.8672588085189911
Quick ratio: 0.5692904112277947
Effective tax rate (%): 12.7715951245363
Interest coverage ratio: 10.994565217391305
COGS to revenue (%): 27.109942399198594
R&D to revenue (%): 25.344352617079892
SG&A to revenue (%): 26.79689456548961
Free cash flow (dilution-adjusted): 2004109589.041096
Buyback yield (%): 1.0367733755885626
Retained earnings: 12050684931.50685
Inventory turnover: 0.3565546772068511
Receivables turnover: 1.0908345854391477
Capitalized R&D asset: 4044732609.855898
ROCI (R&D-adjusted, %): 6.957043560511996
Rosenberg metric: 0.3836928208683922
FCF margin (%): 18.319559228650135
Revenue growth (%): 12.075426305160862
Rule of 40 score: 30.394985533810996
Financial ratios for GSK — quarterly report dated 2025-09-30
Total revenue: 11550000000
Gross profit: 8498648648.648649
Operating income: 3504054054.0540543
Net income: 2897297297.2972975
Capital expenditures: 413513513.5135135
Operating cash flow: 3002702702.7027025
Depreciation & amortization: 997297297.2972974
Net tangible assets: -10586486486.486486
Owner earnings: 3481081081.0810814
Return on net tangible assets (%): -32.88230788869033
Capex to operating income (%): 11.801002699575779
Buffett classification: The Great
Stock price: 42.06
P/E ratio: 11.301926323135298
Shares outstanding: 2002797682
Book value: 21286486486.48649
P/B ratio: 3.9573308896420007
Market cap (USD): 84237670504.92
Debt to equity: 1.1268410360589132
Current ratio: 0.836317615074529
Quick ratio: 0.5495453267085404
Effective tax rate (%): 12.703583061889251
Interest coverage ratio: 15.52694610778443
COGS to revenue (%): 26.418626418626417
R&D to revenue (%): 19.76131976131976
SG&A to revenue (%): 26.196326196326197
Free cash flow (dilution-adjusted): 1814864864.8648648
Buyback yield (%): 0.5085354044226075
Retained earnings: 13535135135.135136
Inventory turnover: 0.36907486106570775
Receivables turnover: 1.0768552349754315
Capitalized R&D asset: 4766647696.620299
ROCI (R&D-adjusted, %): 5.896182526897845
Rosenberg metric: 0.18923592564896932
FCF margin (%): 15.713115713115714
Revenue growth (%): 5.578512396694211
Rule of 40 score: 21.291628109809924
Financial ratios for GSK — quarterly report dated 2025-12-31
Total revenue: 11645945945.945946
Gross profit: 8055405405.405405
Operating income: 2035135135.1351352
Net income: 982432432.4324324
Capital expenditures: 756756756.7567568
Operating cash flow: 3078378378.3783784
Depreciation & amortization: -548648648.6486486
Net tangible assets: -9985135135.135136
Owner earnings: -322972972.972973
Capex to operating income (%): 37.18459495351926
Buffett classification: The Good
Stock price: 48.21
P/E ratio: 11.445815873977903
Shares outstanding: 2002797682
Book value: 21562162162.162163
P/B ratio: 4.477977464553948
Market cap (USD): 96554876249.22
Debt to equity: 1.1105540235648033
Current ratio: 0.8185685568697116
Quick ratio: 0.5416296573325231
Effective tax rate (%): 23.473684210526315
Interest coverage ratio: 8.655172413793103
COGS to revenue (%): 30.830819215595266
R&D to revenue (%): 27.268507774425622
SG&A to revenue (%): 30.621954049663497
Free cash flow (dilution-adjusted): 1693243243.2432432
Buyback yield (%): 0.3526911884404093
Retained earnings: 13795945945.945946
Inventory turnover: 0.44851451721809593
Receivables turnover: 1.4574665990191105
Capitalized R&D asset: 5619864309.514996
ROCI (R&D-adjusted, %): 4.1602572317737385
Rosenberg metric: -0.19419775014801696
FCF margin (%): 14.53933627291715
Revenue growth (%): 0.830700830700829
Rule of 40 score: 15.37003710361798
Financial ratios for GSK — annual report dated 2025-12-31
Total revenue: 44144594594.5946
Gross profit: 31959459459.45946
Operating income: 11267567567.567568
Net income: 8498648648.648649
Capital expenditures: 1789189189.1891892
Operating cash flow: 10460810810.81081
Depreciation & amortization: 3127027027.027027
Net tangible assets: -9985135135.135136
Owner earnings: 9836486486.486486
Return on net tangible assets (%): -98.51130058194613
Capex to operating income (%): 15.879107699688175
Buffett classification: The Great
Stock price: 48.21
P/E ratio: 11.361203438451708
Shares outstanding: 2002797682
Book value: 21562162162.162163
P/B ratio: 4.477977464553948
Market cap (USD): 96554876249.22
Debt to equity: 1.1105540235648033
Current ratio: 0.8185685568697116
Quick ratio: 0.5416296573325231
Effective tax rate (%): 15.024996622078099
Interest coverage ratio: 12.136826783114993
COGS to revenue (%): 27.602779563473838
R&D to revenue (%): 23.035479229803776
SG&A to revenue (%): 27.820124284446074
Free cash flow (dilution-adjusted): 5921621621.621622
Buyback yield (%): 1.9272054225493793
Retained earnings: 13795945945.945946
Inventory turnover: 1.522113436866982
Receivables turnover: 5.524606798579401
Capitalized R&D asset: 18129237431.57715
ROCI (R&D-adjusted, %): 17.759711128912443
Rosenberg metric: 0.506103353783404
FCF margin (%): 13.414148835215967
Revenue growth (%): 12.556335019364093
Rule of 40 score: 25.97048385458006
Financial ratios for HZO — annual report dated 2021-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 48.52
Shares outstanding: 22028154
Market cap (USD): 1068806032.08
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for HZO — annual report dated 2022-09-30
Total revenue: 2308098000
Gross profit: 805754000
Operating income: 265204000
Net income: 197989000
Capital expenditures: 57753000
Operating cash flow: 76595000
Depreciation & amortization: 19418000
Net tangible assets: 536195000
Owner earnings: 159654000
Return on net tangible assets (%): 29.77536157554621
Capex to operating income (%): 21.776820862430434
Buffett classification: The Great
Stock price: 29.79
P/E ratio: 3.314420031718934
Shares outstanding: 22028154
Book value: 782666000
P/B ratio: 0.8384402895487986
Market cap (USD): 656218707.66
Debt to equity: 0.3571881236696113
Current ratio: 1.8266670219879255
Quick ratio: 0.7259164865833923
Effective tax rate (%): 24.40888664902776
Interest coverage ratio: 80.78099299421261
COGS to revenue (%): 65.09013048839347
SG&A to revenue (%): 23.41971614723465
Free cash flow (dilution-adjusted): 2126000
Buyback yield (%): 3.244649954574567
Retained earnings: 630667000
Inventory turnover: 3.306513131686618
Receivables turnover: 45.898502595104105
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 28.213221503427132
FCF margin (%): 0.0921104736453998
Rule of 40 score: 0.0921104736453998
Financial ratios for HZO — annual report dated 2023-09-30
Total revenue: 2394706000
Gross profit: 835329000
Operating income: 200802000
Net income: 109478000
Capital expenditures: 62668000
Operating cash flow: -222235000
Depreciation & amortization: 41032000
Net tangible assets: 316310000
Owner earnings: 87842000
Return on net tangible assets (%): 27.77085770288641
Capex to operating income (%): 31.20885250146911
Buffett classification: The Good
Stock price: 32.82
P/E ratio: 6.603737867699446
Shares outstanding: 22028154
Book value: 918417000
P/B ratio: 0.7871849217512307
Market cap (USD): 722964014.28
Debt to equity: 1.191089668418594
Current ratio: 1.3259870444330848
Quick ratio: 0.366384943492053
Effective tax rate (%): 25.744904534201513
Interest coverage ratio: 3.7626623194108717
COGS to revenue (%): 65.11768041671921
SG&A to revenue (%): 26.497073127139615
Free cash flow (dilution-adjusted): -309300000
Buyback yield (%): 0
Retained earnings: 739949000
Inventory turnover: 1.9184540432808828
Receivables turnover: 27.916833760783398
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 12.755358721834314
FCF margin (%): -12.915990522427387
Revenue growth (%): 3.7523536695582247
Rule of 40 score: -9.163636852869162
Financial ratios for HZO — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 35.27
Shares outstanding: 22028154
Market cap (USD): 776932991.58
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for HZO — annual report dated 2024-09-30
Total revenue: 2431008000
Gross profit: 801196000
Operating income: 128226000
Net income: 38738000
Capital expenditures: 59973000
Operating cash flow: -25660000
Depreciation & amortization: 44487000
Net tangible assets: 346044000
Owner earnings: 23252000
Return on net tangible assets (%): 6.719376726659037
Capex to operating income (%): 46.77132562818773
Buffett classification: The Good
Stock price: 35.27
P/E ratio: 20.056094573287215
Shares outstanding: 22028154
Book value: 986249000
P/B ratio: 0.7877655557369387
Market cap (USD): 776932991.58
Debt to equity: 1.2501437263814716
Current ratio: 1.1908706318986328
Quick ratio: 0.3428633961967669
Effective tax rate (%): 28.70000552170952
Interest coverage ratio: 1.7352459571012924
COGS to revenue (%): 67.04264239360792
SG&A to revenue (%): 27.68275546604536
Free cash flow (dilution-adjusted): -110044000
Buyback yield (%): 0.2755707407463779
Retained earnings: 778015000
Inventory turnover: 1.7976376537129912
Receivables turnover: 22.845887096016316
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 8.348454514380585
FCF margin (%): -4.526681936052864
Revenue growth (%): 1.5159272161175525
Rule of 40 score: -3.010754719935311
Financial ratios for HZO — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 28.95
Shares outstanding: 22028154
Market cap (USD): 637715058.3
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for HZO — quarterly report dated 2025-03-31
Total revenue: 631515000
Gross profit: 189511000
Operating income: 22741000
Net income: 3300000
Capital expenditures: 9803000
Operating cash flow: 72498000
Depreciation & amortization: 12252000
Net tangible assets: 364756000
Owner earnings: 5749000
Return on net tangible assets (%): 1.5761221199925428
Capex to operating income (%): 43.107163273382874
Buffett classification: The Good
Stock price: 21.5
P/E ratio: 35.87919022727273
Shares outstanding: 22028154
Book value: 1003379000
P/B ratio: 0.4720103878992883
Market cap (USD): 473605311
Debt to equity: 1.3290979779325658
Current ratio: 1.1617646284369125
Quick ratio: 0.30738807817280805
Effective tax rate (%): 30.688294607628237
Interest coverage ratio: 1.2509488970790472
COGS to revenue (%): 69.99105326080932
SG&A to revenue (%): 26.407923802284984
Free cash flow (dilution-adjusted): 54518000
Buyback yield (%): 0
Retained earnings: 799385000
Inventory turnover: 0.4540779322176678
Receivables turnover: 5.285175080342796
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.4826777521403018
FCF margin (%): 8.632890746854786
Rule of 40 score: 8.632890746854786
Financial ratios for HZO — quarterly report dated 2025-06-30
Total revenue: 657159000
Gross profit: 199621000
Operating income: 27515000
Net income: -51970000
Capital expenditures: 14271000
Operating cash flow: 84937000
Depreciation & amortization: 12536000
Net tangible assets: 376725000
Owner earnings: -53705000
Return on net tangible assets (%): -14.255756851814985
Capex to operating income (%): 51.86625477012539
Buffett classification: The Good
Stock price: 25.14
Shares outstanding: 22028154
Book value: 951323000
P/B ratio: 0.5821238333983305
Market cap (USD): 553787791.5600001
Debt to equity: 1.3389595331974524
Current ratio: 1.2085750981941161
Quick ratio: 0.29426352647281084
Interest coverage ratio: 1.6246457250826642
COGS to revenue (%): 69.62363750629605
SG&A to revenue (%): 26.189400129953327
Free cash flow (dilution-adjusted): 62854000
Buyback yield (%): 2.717466912300019
Retained earnings: 747239000
Inventory turnover: 0.5048867878515017
Receivables turnover: 6.150352366423645
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.838515342899983
FCF margin (%): 9.56450417631045
Revenue growth (%): 4.060711147003635
Rule of 40 score: 13.625215323314084
Financial ratios for HZO — annual report dated 2025-09-30
Total revenue: 2309288000
Gross profit: 750228000
Operating income: 103072000
Net income: -30766000
Capital expenditures: 50036000
Operating cash flow: 72806000
Depreciation & amortization: 49320000
Net tangible assets: 374843000
Owner earnings: -31482000
Return on net tangible assets (%): -8.398716262541917
Capex to operating income (%): 48.54470661285315
Buffett classification: The Good
Stock price: 25.33
Shares outstanding: 22028154
Book value: 948753000
P/B ratio: 0.5881121227758963
Market cap (USD): 557973140.8199999
Debt to equity: 1.313265939607042
Current ratio: 1.1990080009747381
Quick ratio: 0.3183646738688977
Interest coverage ratio: 1.4484948986761854
COGS to revenue (%): 67.51258396527415
SG&A to revenue (%): 28.02404897093823
Free cash flow (dilution-adjusted): -7411000
Buyback yield (%): 4.924968244818247
Retained earnings: 746384000
Inventory turnover: 1.7975437204840614
Receivables turnover: 21.325428486997637
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 6.938268313993799
FCF margin (%): -0.32092142686403774
Revenue growth (%): -5.006976529900354
Rule of 40 score: -5.327897956764391
Financial ratios for HZO — quarterly report dated 2025-09-30
Total revenue: 552153000
Gross profit: 191442000
Operating income: 13844000
Net income: -82000
Capital expenditures: 13330000
Operating cash flow: 61452000
Depreciation & amortization: 12935000
Net tangible assets: 374843000
Owner earnings: -477000
Return on net tangible assets (%): -0.12725327670518055
Capex to operating income (%): 96.28720023114707
Buffett classification: The Gruesome
Stock price: 25.33
Shares outstanding: 22028154
Book value: 948753000
P/B ratio: 0.5881121227758963
Market cap (USD): 557973140.8199999
Debt to equity: 1.313265939607042
Current ratio: 1.1990080009747381
Quick ratio: 0.3183646738688977
Interest coverage ratio: 0.8003237368481906
COGS to revenue (%): 65.32808841027759
SG&A to revenue (%): 32.16463552674711
Free cash flow (dilution-adjusted): 45087000
Buyback yield (%): 0
Retained earnings: 746384000
Inventory turnover: 0.41588764573494685
Receivables turnover: 5.098930629432624
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0.9319057216211013
FCF margin (%): 8.165671471494313
Revenue growth (%): -15.978781390804963
Rule of 40 score: -7.81310991931065
Financial ratios for HZO — quarterly report dated 2025-12-31
Total revenue: 505178000
Gross profit: 160470000
Operating income: 4920000
Net income: -7926000
Capital expenditures: 2476000
Operating cash flow: 16876000
Depreciation & amortization: 12582000
Net tangible assets: 370902000
Owner earnings: 2180000
Capex to operating income (%): 50.32520325203252
Buffett classification: The Good
Stock price: 24.23
Shares outstanding: 22028154
Book value: 944320000
P/B ratio: 0.565213244895798
Market cap (USD): 533742171.42
Debt to equity: 1.29657319552694
Current ratio: 1.1905224056812307
Quick ratio: 0.28772516724034447
Interest coverage ratio: 0.31029263370333
COGS to revenue (%): 68.23495876700886
SG&A to revenue (%): 30.791127087877936
Free cash flow (dilution-adjusted): 5691000
Buyback yield (%): 0
Retained earnings: 738458000
Inventory turnover: 0.3971766202402131
Receivables turnover: 5.882644743583772
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0.3353833527155826
FCF margin (%): 1.126533617853509
Revenue growth (%): -8.507605681758498
Rule of 40 score: -7.381072063904989
Financial ratios for ICDSLTD.NS — annual report dated 2022-03-31
Total revenue: 168099.6966899644
Gross profit: 104984.8344982197
Operating income: 572622.9724383489
Net income: 769563.4972965845
Capital expenditures: 38981.933271792164
Operating cash flow: -71093.2348674667
Depreciation & amortization: 43782.144270077806
Net tangible assets: 3325042.8590267706
Owner earnings: 774363.7082948702
Return on net tangible assets (%): 23.288833892550905
Capex to operating income (%): 6.80760904610566
Buffett classification: The Great
Stock price: 0.5413424765923777
P/E ratio: 9.16351420590856
Shares outstanding: 13026700
Book value: 3325042.8590267706
P/B ratio: 2.120846659369075
Market cap (USD): 7051906.039825927
Debt to equity: 0.01900149917902101
Current ratio: 14.555208833413346
Quick ratio: 14.555208833413346
Effective tax rate (%): 1.7013105144358724
Interest coverage ratio: 61.85470085470086
COGS to revenue (%): 37.54608927590806
SG&A to revenue (%): 34.07076174786224
Free cash flow (dilution-adjusted): -110075.16813925887
Buyback yield (%): 0
Retained earnings: 719359.0927073718
Receivables turnover: 17.803072625698324
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 16.845968520982776
FCF margin (%): -65.48207421354044
Rule of 40 score: -65.48207421354044
Financial ratios for ICDSLTD.NS — annual report dated 2023-03-31
Total revenue: 275188.7941534714
Gross profit: 201668.69671132768
Operating income: 12289.890377588308
Net income: 46345.91961023143
Capital expenditures: 584.652862362972
Operating cash flow: 774945.1887941535
Depreciation & amortization: 44299.634591961025
Net tangible assets: 3107576.126674787
Owner earnings: 90060.90133982949
Return on net tangible assets (%): 2.898107646238026
Capex to operating income (%): 4.757185332011892
Buffett classification: The Great
Stock price: 0.2131546894031669
P/E ratio: 59.912549277266756
Shares outstanding: 13026700
Book value: 3107576.126674787
P/B ratio: 0.8935266842262045
Market cap (USD): 2776702.192448234
Debt to equity: 0.011582239781760031
Current ratio: 15.721277334258938
Quick ratio: 15.721277334258938
Effective tax rate (%): 28.731972279453082
Interest coverage ratio: 1.611821086261981
COGS to revenue (%): 26.71623954322135
SG&A to revenue (%): 18.209179834462
Free cash flow (dilution-adjusted): 774165.6516443362
Buyback yield (%): 0
Retained earnings: 700889.1595615104
Receivables turnover: 28.347553324968636
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0.38428872308741135
FCF margin (%): 281.3216482981454
Revenue growth (%): 63.70570534759346
Rule of 40 score: 345.02735364573886
Financial ratios for ICDSLTD.NS — annual report dated 2024-03-31
Total revenue: 421141.6236958868
Gross profit: 361398.2491905504
Operating income: 208262.38158052525
Net income: 244058.04053243794
Capital expenditures: 2638.2060199064636
Operating cash flow: 23899.748171243555
Depreciation & amortization: 43578.366710636765
Net tangible assets: 3302446.336491186
Owner earnings: 284998.2012231683
Return on net tangible assets (%): 8.62991165288626
Capex to operating income (%): 1.2667703115103357
Buffett classification: The Great
Stock price: 0.4612523992322457
P/E ratio: 24.619539745424156
Shares outstanding: 13026700
Book value: 3302446.3364911857
P/B ratio: 1.8194380822135523
Market cap (USD): 6008596.629078696
Debt to equity: 0.01303237941690179
Current ratio: 24.80009855453351
Quick ratio: 24.80009855453351
Effective tax rate (%): 13.773672838198534
Interest coverage ratio: 23.823045267489714
COGS to revenue (%): 14.186053133631365
SG&A to revenue (%): 8.519604772345454
Free cash flow (dilution-adjusted): 21921.093656313707
Buyback yield (%): 0
Retained earnings: 932989.5670943758
Receivables turnover: 19.159301691216584
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 6.190737598562731
FCF margin (%): 5.205159600216407
Revenue growth (%): 53.03734477684372
Rule of 40 score: 58.24250437706012
Financial ratios for ICDSLTD.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 3449558.0506450073
Buffett classification: The Gruesome
Stock price: 0.4777830864787387
Shares outstanding: 13026700
Book value: 3449558.050645007
P/B ratio: 1.8042708199877426
Market cap (USD): 6223936.932632585
Debt to equity: 0.003881619268898223
Current ratio: 27.905812973883744
Quick ratio: 27.905812973883744
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ICDSLTD.NS — quarterly report dated 2024-12-31
Total revenue: 59564.05175428371
Operating income: 8299.33558689824
Net income: -90196.99265648676
Capital expenditures: 0
Depreciation & amortization: 10840.42429187551
Owner earnings: -79356.56836461126
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.7343513229980184
Shares outstanding: 13026700
Market cap (USD): 9566174.379298287
Effective tax rate (%): 275.26613816534547
Interest coverage ratio: 4.045454545454546
COGS to revenue (%): 0
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ICDSLTD.NS — annual report dated 2025-03-31
Total revenue: 456137.47954173485
Gross profit: 218950.19873743277
Operating income: 198047.69698386718
Net income: 163993.45335515548
Capital expenditures: 12134.673836801496
Operating cash flow: 123532.8501285948
Depreciation & amortization: 43044.18985270049
Net tangible assets: 3383586.6261398173
Owner earnings: 194902.96937105447
Return on net tangible assets (%): 5.76024765748086
Capex to operating income (%): 6.127147157782894
Buffett classification: The Great
Stock price: 0.513595518730307
P/E ratio: 40.797084316254875
Shares outstanding: 13026700
Book value: 3383586.6261398173
P/B ratio: 1.9773262762528796
Market cap (USD): 6690454.74384409
Debt to equity: 0.014214046822742476
Current ratio: 4.960023910931779
Quick ratio: 4.960023910931779
Effective tax rate (%): 52.14083449899355
Interest coverage ratio: 21.691421254801536
COGS to revenue (%): 9.859552001640267
SG&A to revenue (%): 9.759598134194475
Free cash flow (dilution-adjusted): 111316.34323123684
Buyback yield (%): 0
Retained earnings: 1073684.8258124853
Receivables turnover: 44.03837471783296
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 5.739132202287387
FCF margin (%): 24.404121174842377
Revenue growth (%): 8.309759443564078
Rule of 40 score: 32.713880618406456
Financial ratios for ICDSLTD.NS — quarterly report dated 2025-03-31
Total revenue: 274245.96679915825
Operating income: 165863.9233107318
Net income: 97743.74561608603
Capital expenditures: 0
Depreciation & amortization: 10720.13093289689
Net tangible assets: 3383586.6261398173
Owner earnings: 108463.87654898292
Return on net tangible assets (%): 3.2055888775256363
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.513595518730307
P/E ratio: 17.112232352243257
Shares outstanding: 13026700
Book value: 3383586.6261398173
P/B ratio: 1.9773262762528796
Market cap (USD): 6690454.74384409
Debt to equity: 0.014214046822742476
Current ratio: 4.960023910931779
Quick ratio: 4.960023910931779
Effective tax rate (%): 8.53298326222514
Interest coverage ratio: 66.61032863849765
COGS to revenue (%): 0
Buyback yield (%): 0
Retained earnings: 1073684.8258124853
Receivables turnover: 26.477426636568847
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.806493576887636
Revenue growth (%): 360.42194699999584
Rule of 40 score: 360.42194699999584
Financial ratios for ICDSLTD.NS — quarterly report dated 2025-06-30
Total revenue: 90252.7498244793
Operating income: 31991.575005850693
Net income: 161104.61034402062
Capital expenditures: 0
Depreciation & amortization: 10812.075824947344
Owner earnings: 171916.68616896798
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.6785630704423122
P/E ratio: 52.41248796677318
Shares outstanding: 13026700
Market cap (USD): 8839437.549730869
Effective tax rate (%): 10.096059596157616
Interest coverage ratio: 16.98136645962733
COGS to revenue (%): 0
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -67.0905826335907
Rule of 40 score: -67.0905826335907
Financial ratios for ICDSLTD.NS — quarterly report dated 2025-09-30
Total revenue: 59650.50732807215
Operating income: 90.19165727170237
Net income: -35603.156708004506
Capital expenditures: 0
Depreciation & amortization: 10676.437429537767
Net tangible assets: 3382559.1882750844
Owner earnings: -24926.71927846674
Return on net tangible assets (%): -0.7369189389167191
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.612739571589628
P/E ratio: 59.99310160930537
Shares outstanding: 13026700
Book value: 3382559.1882750844
P/B ratio: 2.359744244799739
Market cap (USD): 7981974.577226607
Debt to equity: 0.002916345868621118
Current ratio: 7.122335126519228
Quick ratio: 7.122335126519228
Interest coverage ratio: 0.053691275167785234
COGS to revenue (%): 0
Buyback yield (%): 0
Receivables turnover: 5.905133928571429
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0.0026161146119811508
Revenue growth (%): -33.9072688155446
Rule of 40 score: -33.9072688155446
Financial ratios for ICDSLTD.NS — quarterly report dated 2025-12-31
Total revenue: 63829.78723404255
Operating income: 17567.1159630166
Net income: 50696.22368274479
Capital expenditures: 0
Depreciation & amortization: 10627.158293416509
Owner earnings: 61323.3819761613
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.5098585273476663
P/E ratio: 24.245234645581498
Shares outstanding: 13026700
Market cap (USD): 6641774.078199845
Effective tax rate (%): 13.24818909645444
Interest coverage ratio: 9.918238993710693
COGS to revenue (%): 0
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 7.006277219043186
Rule of 40 score: 7.006277219043186
Financial ratios for ICICIAMC.NS — quarterly report dated 2025-12-31
Total revenue: 168727860.08688873
Gross profit: 138158627.6038766
Operating income: 124133897.73866549
Net income: 102159964.35334745
Capital expenditures: 0
Depreciation & amortization: 2894062.6044335524
Owner earnings: 105054026.957781
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 29.373844268686643
P/E ratio: 39.37087567801962
Shares outstanding: 494258520
Market cap (USD): 14518272794.951542
Effective tax rate (%): 24.754676731211028
Interest coverage ratio: 249.8542600896861
COGS to revenue (%): 18.117477734423996
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 6.727338261310367
Rule of 40 score: 6.727338261310367
Financial ratios for IHC.L — annual report dated 2022-01-31
Total revenue: 54733333.333333336
Gross profit: 27456000
Operating income: 5673333.333333333
Net income: 5645333.333333333
Capital expenditures: 5294666.666666667
Operating cash flow: 4768000
Depreciation & amortization: 2541333.3333333335
Net tangible assets: 26218666.666666668
Owner earnings: 2891999.999999999
Return on net tangible assets (%): 11.030309194467042
Capex to operating income (%): 93.32549941245595
Buffett classification: The Gruesome
Stock price: 0.013466666666666667
P/E ratio: 0.21388759026924895
Shares outstanding: 89663372
Book value: 47318666.666666664
P/B ratio: 0.025517767680126237
Market cap (USD): 1207466.7429333334
Debt to equity: 0.21254473217053174
Current ratio: 3.2390262851223617
Quick ratio: 2.403988087530752
Effective tax rate (%): -6.838253848094878
Interest coverage ratio: 14.136212624584717
COGS to revenue (%): 49.836784409257
R&D to revenue (%): 0.8477466504263093
SG&A to revenue (%): 39.79780755176614
Free cash flow (dilution-adjusted): -712000
Buyback yield (%): 0
Retained earnings: 34300000
Inventory turnover: 3.1722747712823693
Receivables turnover: 5.003656752803511
Capitalized R&D asset: 464000
ROCI (R&D-adjusted, %): 10.500081903915007
FCF margin (%): -1.3008526187576126
Rule of 40 score: -1.3008526187576126
Financial ratios for IHC.L — annual report dated 2023-01-31
Total revenue: 50904938.27160493
Gross profit: 22337037.037037037
Operating income: 1839506.172839506
Net income: 335802.4691358025
Capital expenditures: 7686419.753086419
Operating cash flow: -4285185.185185185
Depreciation & amortization: 2820987.6543209874
Net tangible assets: 22802469.135802466
Owner earnings: -4529629.629629629
Return on net tangible assets (%): -19.864645370871685
Capex to operating income (%): 417.85234899328856
Buffett classification: The Gruesome
Stock price: 0.006296296296296296
P/E ratio: 1.681188225
Shares outstanding: 89663372
Book value: 43795061.72839507
P/B ratio: 0.012890657867734114
Market cap (USD): 564547.1570370371
Debt to equity: 0.3686361842476179
Current ratio: 2.6069883167459973
Quick ratio: 1.5322371267849415
Effective tax rate (%): -257.89473684210526
Interest coverage ratio: 3.7721518987341773
COGS to revenue (%): 56.12009797977349
R&D to revenue (%): 0.28132806247423175
SG&A to revenue (%): 9.390536706036427
Free cash flow (dilution-adjusted): -14746913.580246912
Buyback yield (%): 0
Retained earnings: 31577777.777777776
Inventory turnover: 2.3291394061399093
Receivables turnover: 4.0715907968796285
Capitalized R&D asset: 454089.8765432099
ROCI (R&D-adjusted, %): 3.1336850788643593
Rosenberg metric: -11.032247765006385
FCF margin (%): -28.96951470909223
Revenue growth (%): -6.9946316596743054
Rule of 40 score: -35.964146368766535
Financial ratios for IHC.L — annual report dated 2024-01-31
Total revenue: 47632911.39240506
Gross profit: 22641772.151898734
Operating income: -229113.9240506329
Net income: -7637974.683544303
Capital expenditures: 549367.088607595
Operating cash flow: 2546835.4430379746
Depreciation & amortization: 3084810.1265822784
Net tangible assets: 19860759.493670885
Owner earnings: -5102531.64556962
Return on net tangible assets (%): -25.691523263224987
Buffett classification: The Gruesome
Stock price: 0.004810126582278481
Shares outstanding: 89663372
Book value: 36668354.43037974
P/B ratio: 0.011761972300469485
Market cap (USD): 431292.1691139241
Debt to equity: 0.4429025131179233
Current ratio: 2.406292463677224
Quick ratio: 0.9697919933103375
Interest coverage ratio: -0.2234567901234568
COGS to revenue (%): 52.46611745947383
R&D to revenue (%): 0.3135795907520595
SG&A to revenue (%): 11.267605633802816
Free cash flow (dilution-adjusted): 546835.4430379746
Buyback yield (%): 0
Retained earnings: 24207594.93670886
Inventory turnover: 1.4365858982754856
Receivables turnover: 4.9689687046084785
Capitalized R&D asset: 398437.7058915455
ROCI (R&D-adjusted, %): -0.6595077682334705
Rosenberg metric: 2.127891750327367
FCF margin (%): 1.1480201966516077
Revenue growth (%): -6.427719962534607
Rule of 40 score: -5.279699765883
Financial ratios for IHC.L — quarterly report dated 2025-01-31
Capital expenditures: 0
Net tangible assets: 14127500
Buffett classification: The Gruesome
Stock price: 0.001625
Shares outstanding: 89663372
Book value: 20793750
P/B ratio: 0.0070070564232040874
Market cap (USD): 145702.9795
Debt to equity: 0.9002103997595431
Current ratio: 2.125760649087221
Quick ratio: 1.020030425963489
Buyback yield (%): 0
Retained earnings: 5196250
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IHC.L — annual report dated 2025-01-31
Total revenue: 47813750
Gross profit: 20472500
Operating income: -2377500
Net income: -18708750
Capital expenditures: 661250
Operating cash flow: -1936250
Depreciation & amortization: 2761250
Net tangible assets: 14127500
Owner earnings: -16608750
Return on net tangible assets (%): -117.56326313926739
Buffett classification: The Gruesome
Stock price: 0.001625
Shares outstanding: 89663372
Book value: 20793750
P/B ratio: 0.0070070564232040874
Market cap (USD): 145702.9795
Debt to equity: 0.9002103997595431
Current ratio: 2.125760649087221
Quick ratio: 1.020030425963489
Interest coverage ratio: -1.7354014598540146
COGS to revenue (%): 57.182818749836606
R&D to revenue (%): 0.6457347520326266
SG&A to revenue (%): 12.491176701262711
Free cash flow (dilution-adjusted): -4255000
Buyback yield (%): 0
Retained earnings: 5196250
Inventory turnover: 1.671864251318505
Receivables turnover: 4.092329089547448
Capitalized R&D asset: 456085.2086263479
ROCI (R&D-adjusted, %): -6.129666188217307
Rosenberg metric: -14.523093220338986
FCF margin (%): -8.899113748660167
Revenue growth (%): 0.37965054477810334
Rule of 40 score: -8.519463203882063
Financial ratios for JBMA.NS — annual report dated 2022-03-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 2.867598575761572
Shares outstanding: 236494264
Market cap (USD): 678170614.6221812
Buyback yield (%): 0
Retained earnings: 103127363.8401688
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JBMA.NS — annual report dated 2023-03-31
Total revenue: 429824774.66504264
Gross profit: 85050292.32643119
Operating income: 33453605.359317906
Net income: 15241352.009744216
Capital expenditures: 75237734.47015835
Operating cash flow: 58970426.30937881
Depreciation & amortization: 15872704.01948843
Net tangible assets: 98729707.67356883
Owner earnings: -44123678.44092571
Return on net tangible assets (%): -44.69138973530878
Capex to operating income (%): 224.90172183848705
Buffett classification: The Gruesome
Stock price: 3.9103532277710116
P/E ratio: 60.675464223285104
Shares outstanding: 236494264
Book value: 125557393.42265528
P/B ratio: 7.3653656178471225
Market cap (USD): 924776108.5817298
Debt to equity: 1.6522941500710793
Current ratio: 0.9031195067969079
Quick ratio: 0.6593562546780641
Effective tax rate (%): 26.18991020558397
Interest coverage ratio: 2.2732145414035037
COGS to revenue (%): 80.21279894982558
SG&A to revenue (%): 3.3597805796509888
Free cash flow (dilution-adjusted): -17366540.803897686
Buyback yield (%): 0
Retained earnings: 110726431.181486
Inventory turnover: 6.677573029063948
Receivables turnover: 7.522171774014767
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 15.248836589155173
FCF margin (%): -4.040376876235491
Rule of 40 score: -4.040376876235491
Financial ratios for JBMA.NS — annual report dated 2024-03-31
Total revenue: 600713514.8099293
Gross profit: 125779529.91965464
Operating income: 49729595.87480513
Net income: 23231214.77395371
Capital expenditures: 26892696.96606308
Operating cash flow: 24558999.880081546
Depreciation & amortization: 20562981.172802493
Net tangible assets: 108926921.69324858
Owner earnings: 16901498.98069312
Return on net tangible assets (%): 15.516365208859744
Capex to operating income (%): 54.0778514142077
Buffett classification: The Good
Stock price: 10.798584452975048
P/E ratio: 109.92982103163372
Shares outstanding: 236494264
Book value: 142952728.14486146
P/B ratio: 17.864669779930846
Market cap (USD): 2553803282.4481764
Debt to equity: 1.784139071547715
Current ratio: 0.931578349975425
Quick ratio: 0.6678796643424744
Effective tax rate (%): 21.28157471714612
Interest coverage ratio: 2.296938947893155
COGS to revenue (%): 73.34904728158344
SG&A to revenue (%): 3.271656003273878
Free cash flow (dilution-adjusted): -2735076.148219211
Buyback yield (%): 0
Retained earnings: 125872586.64108406
Inventory turnover: 4.940784843372606
Receivables turnover: 7.472208652329401
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 20.28190369654901
FCF margin (%): -0.4553045804345873
Revenue growth (%): 39.757768797310064
Rule of 40 score: 39.30246421687548
Financial ratios for JBMA.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 113833014.81127568
Buffett classification: The Gruesome
Stock price: 10.728021978021978
Shares outstanding: 236494264
Book value: 150306975.6330626
P/B ratio: 16.87956032101846
Market cap (USD): 2537115661.868132
Debt to equity: 2.094908492732662
Current ratio: 0.9155548119954828
Quick ratio: 0.7186380303093675
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JBMA.NS — quarterly report dated 2024-12-31
Total revenue: 162740412.6355053
Gross profit: 55062361.58060379
Operating income: 15217391.304347824
Net income: 6580020.981466371
Capital expenditures: 0
Depreciation & amortization: 5182422.193728873
Owner earnings: 11762443.175195243
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 8.890663247464738
P/E ratio: 79.88541628906997
Shares outstanding: 236494264
Market cap (USD): 2102590861.1810231
Effective tax rate (%): 22.405498281786944
Interest coverage ratio: 1.906396028037383
COGS to revenue (%): 66.16552662679511
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JBMA.NS — quarterly report dated 2025-03-31
Total revenue: 192389525.36824876
Gross profit: 57979892.44797755
Operating income: 17866495.20692074
Net income: 8420621.931260228
Capital expenditures: 0
Depreciation & amortization: 5161328.033668458
Net tangible assets: 129956605.09703062
Owner earnings: 13581949.964928687
Return on net tangible assets (%): 10.451142483129564
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 6.897070836737075
P/E ratio: 48.42628325452815
Shares outstanding: 236494264
Book value: 162062567.2200141
P/B ratio: 10.064740546011553
Market cap (USD): 1631117691.2899988
Debt to equity: 1.8973540182842863
Current ratio: 1.068972637246037
Quick ratio: 0.8718212682100372
Effective tax rate (%): 20.400044203779423
Interest coverage ratio: 2.2813852813852815
COGS to revenue (%): 69.86328006319499
Buyback yield (%): 0
Retained earnings: 144099041.38414776
Inventory turnover: 1.8844180748365102
Receivables turnover: 1.6340979048753848
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 5.547435473539481
Revenue growth (%): 18.21865402243357
Rule of 40 score: 18.21865402243357